譽衡藥業(002437.SZ)控股股東、一致行動人及質權人均未減持公司股票
格隆匯8月19日丨譽衡藥業(002437.SZ)公佈,2019年8月19日,公司收到公司控股股東譽衡集團及一致行動人譽衡國際、健康科技的《告知函》,截至2019年8月19日,譽衡集團、譽衡國際、健康科技的減持計劃時間已過半。在此期間內,譽衡集團、譽衡國際、健康科技及其質權人均未通過集中競價交易的方式減持公司股票。
據悉,公司於2019年6月13日披露了《關於控股股東及一致行動人可能減持公司股票的預披露公告》,譽衡集團及一致行動人譽衡國際、健康科技及其質權人自公告發布之日起15個交易日後的90個自然日內,可能通過集中競價交易方式減持公司股份將合計不超過約2198.12萬股,不超過公司總股本的1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.